Centaurus Financial Snaps Up New Stake in Biotech Giant Amgen
Centaurus Financial Inc., a financial institution, has acquired a new stake in Amgen Inc. (NASDAQ: AMGN) worth approximately $1,236,000. The company purchased 3,413 shares of the medical research firm's stock during the second quarter, according to its latest SEC filing.
Centaurus Financial is not the only institution that has added to or reduced its stake in Amgen this year. Adell Harriman & Carpenter Inc., for example, increased its stake by 7.9% in the fourth quarter and now owns 22,008 shares of the company's stock worth $7,204,000.
Amgen's recent earnings report showed that the medical research company beat analysts' expectations with a net margin of 22.95% and a return on equity of 124.14%. The company's revenue was up 9.5% year-over-year during the quarter, driven by the success of its biologic medicines.
Despite this positive news, not all analysts are bullish on Amgen. Some have expressed caution about the company's partnership strategy and the potential risks associated with it.